About Alder BioPharmaceuticals (NASDAQ:ALDR)
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ALDR
- CUSIP: N/A
- Web: www.alderbio.com
- Market Cap: $778.71 million
- Outstanding Shares: 67,713,000
- 50 Day Moving Avg: $11.22
- 200 Day Moving Avg: $14.18
- 52 Week Range: $8.60 - $34.30
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.88
- P/E Growth: -0.09
- Annual Revenue: $683,000.00
- Price / Sales: 1,140.12
- Book Value: $4.35 per share
- Price / Book: 2.64
- EBITDA: ($257,760,000.00)
- Return on Equity: -78.68%
- Return on Assets: -72.72%
- Current Ratio: 7.23%
- Quick Ratio: 7.20%
- Average Volume: 1.30 million shs.
- Beta: 2.62
- Short Ratio: 3.45
Frequently Asked Questions for Alder BioPharmaceuticals (NASDAQ:ALDR)
What is Alder BioPharmaceuticals' stock symbol?
Alder BioPharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
How were Alder BioPharmaceuticals' earnings last quarter?
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.48) earnings per share for the quarter, beating analysts' consensus estimates of ($1.67) by $0.19. The company had revenue of $0.68 million for the quarter. Alder BioPharmaceuticals's quarterly revenue was up 518.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.79) EPS. View Alder BioPharmaceuticals' Earnings History.
Where is Alder BioPharmaceuticals' stock going? Where will Alder BioPharmaceuticals' stock price be in 2017?
11 brokers have issued 1-year price objectives for Alder BioPharmaceuticals' stock. Their forecasts range from $11.00 to $51.00. On average, they expect Alder BioPharmaceuticals' stock price to reach $31.55 in the next year. View Analyst Ratings for Alder BioPharmaceuticals.
What are analysts saying about Alder BioPharmaceuticals stock?
Here are some recent quotes from research analysts about Alder BioPharmaceuticals stock:
- 1. Mizuho analysts commented, "We received an email from Alder yesterday on its recap of the 18th Congress of the International Headache Society (IHC) meeting as it relates to eptinezumab. What we found as incremental data points are Alder’s interviews with practicing physicians on the advantages of eptinezumab. We believe the IV formulation for eptinezumab is a positive differentiation from other CGRP products in late stage development because of its reimbursement and potentially better compliance." (9/15/2017)
- 2. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (8/8/2017)
- 3. Needham & Company LLC analysts commented, "Results from the ongoing pivotal Phase 3 PROMISE-1 trial in patients with frequent episodic migraines (FEM) are expected this month. In the context of positive Phase 3 FEM results from all competitor CGRP antibody programs (AMGN, LLY, TEVA), we think PROMISE-1’s primary endpoint will generally be in-line with the competition. However, we expect differentiation with key secondary endpoints (≥75% reduction in migraine days over weeks 1-12 and weeks 1-4), which we think will be important for commercial success. We maintain our view that there is room for multiple players in the migraine prophylaxis market, and we believe Alder shares remain underappreciated even in a scenario where PROMISE-1 data are positive but undifferentiated. Alder’s current EV (~$550M) reflects treatment of just ~63k patients with eptinezumab in 2027 in our model, or <1% of our estimated 7.1M prevention therapy candidates."" (6/9/2017)
- 4. Aegis analysts commented, "We conducted an in-depth analysis of four late-stage monoclonal antibodies in development for migraine prevention – See table 1." (4/10/2017)
Who are some of Alder BioPharmaceuticals' key competitors?
Some companies that are related to Alder BioPharmaceuticals include Radius Health (RDUS), AnaptysBio (ANAB), Five Prime Therapeutics (FPRX), Clinigen Group PLC (CLIN), Ascendis Pharma A/S (ASND), Acorda Therapeutics (ACOR), Dermira (DERM), Lexicon Pharmaceuticals (LXRX), MyoKardia (MYOK), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), NeuroDerm (NDRM), REGENXBIO (RGNX), Xencor (XNCR), Epizyme (EPZM), Athenex (ATNX), Retrophin (RTRX) and Amarin Corporation PLC (AMRN).
Who are Alder BioPharmaceuticals' key executives?
Alder BioPharmaceuticals' management team includes the folowing people:
- Stephen M. Dow, Independent Chairman of the Board
- Randall C. Schatzman Ph.D., President, Chief Executive Officer, Director
- Larry K. Benedict, Executive Vice President, Principal Accounting Officer
- James B. Bucher J.D., Senior Vice President, General Counsel
- Randal A. Hassler, Senior Vice President - Pharmaceutical Operations
- John A. Latham Ph.D., Chief Scientific Officer
- Mark James Litton Ph.D., Chief Business Officer, Treasurer and Secretary
- Elisabeth A. Sandoval, Chief Commercial Officer
- Jeffrey T.L. Smith M.D., Managing Director of Alder BioPharmaceuticals Limited
- Timothy M. Whitaker M.D., Chief Medical Officer
Who owns Alder BioPharmaceuticals stock?
Alder BioPharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Quantitative Systematic Strategies LLC (0.02%). Company insiders that own Alder BioPharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton, Randall C Schatzman and Stephen M Dow. View Institutional Ownership Trends for Alder BioPharmaceuticals.
Who bought Alder BioPharmaceuticals stock? Who is buying Alder BioPharmaceuticals stock?
How do I buy Alder BioPharmaceuticals stock?
Shares of Alder BioPharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alder BioPharmaceuticals' stock price today?
MarketBeat Community Rating for Alder BioPharmaceuticals (NASDAQ ALDR)MarketBeat's community ratings are surveys of what our community members think about Alder BioPharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Alder BioPharmaceuticals stock can currently be purchased for approximately $11.50.
Consensus Ratings for Alder BioPharmaceuticals (NASDAQ:ALDR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 10 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.91)|
|Consensus Price Target: ||$31.55 (174.31% upside)|Consensus Price Target History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Analysts' Ratings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/26/2017||Cowen and Company||Initiated Coverage||Outperform||$20.00||Low|
|9/14/2017||Royal Bank Of Canada||Initiated Coverage||Outperform -> Outperform||$17.00||High|
|8/24/2017||Credit Suisse Group||Set Price Target||Hold||$17.00 -> $11.00||High|
|8/10/2017||Needham & Company LLC||Reiterated Rating||Buy||$36.00 -> $26.00||High|
|8/9/2017||BMO Capital Markets||Reiterated Rating||Outperform||$39.00 -> $27.00||Medium|
|6/28/2017||Wells Fargo & Company||Reiterated Rating||Outperform||$51.00||High|
|6/28/2017||Piper Jaffray Companies||Reiterated Rating||Overweight||$47.00||High|
|6/12/2017||Leerink Swann||Reiterated Rating||Outperform||$32.00||Medium|
|4/17/2017||Jefferies Group LLC||Reiterated Rating||Buy||$43.00||Low|
|9/30/2016||Brean Capital||Initiated Coverage||Buy||$45.00||N/A|
|9/13/2016||J P Morgan Chase & Co||Initiated Coverage||Overweight||$40.00||N/A|
Earnings History for Alder BioPharmaceuticals (NASDAQ:ALDR)Earnings History by Quarter for Alder BioPharmaceuticals (NASDAQ ALDR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||Q2 2017||($1.67)||($1.48)||$0.68 million||View||Listen|
|7/26/2016||Q2||($0.75)||($0.79)||$1.14 million||$0.11 million||View||Listen|
|3/4/2015||Q414||($0.18)||($0.22)||$5.70 million||$6.40 million||View||N/A|
|11/3/2014||Q314||$0.05||$0.88||$14.84 million||$38.75 million||View||N/A|
|8/5/2014||Q2||($0.22)||($0.40)||$5.00 million||$4.70 million||View||N/A|
|6/20/2014||Q1||($0.22)||($5.38)||$4.60 million||$4.80 million||View||N/A|
Earnings Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)
2017 EPS Consensus Estimate: ($3.89)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Alder BioPharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Insider Ownership Percentage: 10.60%Insider Trades by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)
Institutional Ownership Percentage: 76.16%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/16/2017||Mark James Litton||Insider||Sell||16,520||$12.33||$203,691.60|| |
|7/18/2017||Stephen M Dow||Director||Buy||25,000||$10.00||$250,000.00|| |
|6/20/2017||Jeffrey T L Smith||VP||Sell||585||$20.00||$11,700.00|| |
|1/18/2017||Mark James Litton||Insider||Sell||1,498||$23.10||$34,603.80|| |
|1/9/2017||Mark James Litton||Insider||Sell||9,516||$23.01||$218,963.16|| |
|12/1/2016||Jeffrey T. L. Smith||VP||Sell||3,000||$22.78||$68,340.00|| |
|12/1/2016||John A. Latham||Insider||Sell||3,636||$22.78||$82,828.08|| |
|11/7/2016||Randall C Schatzman||CEO||Sell||10,000||$25.16||$251,600.00|| |
|10/17/2016||Mark James Litton||Insider||Sell||6,000||$27.50||$165,000.00|| |
|10/3/2016||Jeffrey T L Smith||VP||Sell||3,000||$31.14||$93,420.00|| |
|10/3/2016||John A Latham||Insider||Sell||10,000||$31.32||$313,200.00|| |
|10/3/2016||Randall C Schatzman||CEO||Sell||8,181||$31.15||$254,838.15|| |
|9/1/2016||Jeffrey T L Smith||VP||Sell||3,000||$32.49||$97,470.00|| |
|9/1/2016||Randall C Schatzman||Insider||Sell||10,000||$32.48||$324,800.00|| |
|8/15/2016||Jeffrey T L Smith||VP||Sell||3,000||$31.17||$93,510.00|| |
|8/1/2016||John A Latham||Insider||Sell||10,000||$31.19||$311,900.00|| |
|7/27/2016||John A Latham||Insider||Sell||10,000||$30.14||$301,400.00|| |
|7/25/2016||Randall C Schatzman||Insider||Sell||10,000||$28.08||$280,800.00|| |
|6/13/2016||Mark James Litton||Insider||Sell||6,000||$28.94||$173,640.00|| |
|6/3/2016||Jeffrey T L Smith||VP||Sell||16,090||$30.20||$485,918.00|| |
|6/1/2016||John A Latham||Insider||Sell||10,000||$30.02||$300,200.00|| |
|5/31/2016||Mark James Litton||Insider||Sell||25,000||$30.05||$751,250.00|| |
|5/27/2016||John A Latham||Insider||Sell||6,401||$30.05||$192,350.05|| |
|5/24/2016||Randall C Schatzman||CEO||Sell||10,000||$28.02||$280,200.00|| |
|4/18/2016||Randall C Schatzman||CEO||Sell||30,000||$28.07||$842,100.00|| |
|1/4/2016||Mark James Litton||insider||Sell||25,000||$31.40||$785,000.00|| |
|1/4/2016||Randall C. Schatzman||CEO||Sell||10,000||$31.47||$314,700.00|| |
|12/1/2015||Jeffrey T. L. Smith||VP||Sell||4,272||$37.24||$159,089.28|| |
|12/1/2015||John A. Latham||insider||Sell||4,550||$37.24||$169,442.00|| |
|12/1/2015||Randall C. Schatzman||CEO||Sell||10,000||$37.24||$372,400.00|| |
|11/30/2015||Stephen M Dow||Director||Sell||88||$37.11||$3,265.68|| |
|11/2/2015||Jeffrey T. L. Smith||VP||Sell||3,900||$33.67||$131,313.00|| |
|11/2/2015||John A. Latham||insider||Sell||4,545||$33.69||$153,121.05|| |
|11/2/2015||Randall C. Schatzman||CEO||Sell||10,000||$33.71||$337,100.00|| |
|10/1/2015||Jeffrey T. L. Smith||VP||Sell||3,900||$32.25||$125,775.00|| |
|10/1/2015||John A. Latham||insider||Sell||4,545||$32.26||$146,621.70|| |
|9/1/2015||Jeffrey T. L. Smith||VP||Sell||3,900||$38.50||$150,150.00|| |
|9/1/2015||John A. Latham||insider||Sell||4,545||$38.52||$175,073.40|| |
|8/31/2015||Stephen M Dow||Director||Sell||16,218||$38.75||$628,447.50|| |
|6/12/2015||Larry Benedict||VP||Sell||25,454||$47.46||$1,208,046.84|| |
|6/4/2015||John A Latham||Insider||Sell||25,000||$44.18||$1,104,500.00|| |
|6/1/2015||Jeffrey T L Smith||VP||Sell||3,900||$41.53||$161,967.00|| |
|6/1/2015||John A Latham||Insider||Sell||4,545||$41.53||$188,753.85|| |
|5/22/2015||Jeffrey T L Smith||VP||Sell||61,818||$38.86||$2,402,247.48|| |
|5/21/2015||Stephen M Dow||Director||Sell||20,000||$65.69||$1,313,800.00|| |
|5/20/2015||Stephen M Dow||Director||Sell||8,462||$40.39||$341,780.18|| |
|5/18/2015||Clay B Siegall||Director||Sell||38,181||$37.62||$1,436,369.22|| |
|4/1/2015||Jeffrey T L Smith||VP||Sell||3,900||$27.43||$106,977.00|| |
|4/1/2015||John A Latham||Insider||Sell||19,045||$29.54||$562,589.30|| |
|3/30/2015||John A Latham||Insider||Sell||14,500||$30.20||$437,900.00|| |
|1/27/2015||Jeffrey T L Smith||VP||Sell||3,900||$28.01||$109,239.00|| |
|1/27/2015||John A Latham||Insider||Sell||15,045||$28.33||$426,224.85|| |
|1/27/2015||Randall C Schatzman||CEO||Sell||100,000||$28.42||$2,842,000.00|| |
|1/26/2015||Jeffrey T L Smith||VP||Sell||2,700||$27.89||$75,303.00|| |
|1/26/2015||Mark James Litton||Insider||Sell||5,200||$28.03||$145,756.00|| |
|1/26/2015||Randall C Schatzman||CEO||Sell||36,422||$27.93||$1,017,266.46|| |
|11/24/2014||Jeffrey T L Smith||VP||Sell||29,090||$16.08||$467,767.20|| |
|5/13/2014||A/S Novo||Insider||Buy||550,000||$10.00||$5,500,000.00|| |
|5/13/2014||Alan Bruce Montgomery||Director||Buy||3,000||$10.00||$30,000.00|| |
|5/13/2014||West 8 Limited Partne Ventures||Major Shareholder||Buy||250,000||$10.00||$2,500,000.00|| |
Headline Trends for Alder BioPharmaceuticals (NASDAQ:ALDR)
Latest Headlines for Alder BioPharmaceuticals (NASDAQ:ALDR)
Loading headlines, please wait.
Alder BioPharmaceuticals (ALDR) Chart for Monday, October, 23, 2017